Genocea Biosciences (LTS:0A51) Total Operating Expense: $57.36 Mil (TTM As of Mar. 2022)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LTS:0A51 Genocea Biosciences Inc LTS:0A51
16 GF Score
Price $0.00
View Full Analysis

What is Genocea Biosciences Total Operating Expense?

Genocea Biosciences LTS:0A51 16 Total Operating Expense is $57.36 Mil as of Mar. 2022. GuruFocus rates LTS:0A51 with a GF Score™ of 16/100.

Genocea Biosciences's Total Operating Expense for the three months ended in Mar. 2022 was $16.04 Mil. Genocea Biosciences's Total Operating Expense for the trailing twelve months (TTM) ended in Mar. 2022 was $57.36 Mil.

Genocea Biosciences Total Operating Expense Related Terms

Genocea Biosciences Total Operating Expense Historical Data

* Premium members only.

The historical data trend for Genocea Biosciences's Total Operating Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Genocea Biosciences Total Operating Expense Chart

Genocea Biosciences Annual Data
Trend Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21
Total Operating Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only 52.64 39.52 38.99 48.35 53.73

Genocea Biosciences Quarterly Data
Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22
Total Operating Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 12.42 14.55 13.36 13.41 16.04
LTS:0A51
16GF Score
Genocea Biosciences Inc LTS:0A51
Total Operating Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Genocea Biosciences Total Operating Expense Calculation

Total Operating Expense is the primary recurring expense associated with central operations that are incurred in order to generate sales.


Total Operating Expense for the trailing twelve months (TTM) ended in Mar. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $57.36 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Total Operating Expense of $57.36 Mil mean?
Genocea Biosciences (LTS:0A51) has a Total Operating Expense of $57.36 Mil as of Mar. 2022. Total operating expense is the primary recurring expense associated with central operations. View historical data on Genocea Biosciences and its competitors.
Is Genocea Biosciences' Total Operating Expense too high?
Genocea Biosciences' current Total Operating Expense is $57.36 Mil. Overall, Genocea Biosciences has a GF Score™ of 16/100, reflecting its overall financial health beyond just this single metric.
How does Genocea Biosciences' Total Operating Expense compare to FNAM and BXRX?
Genocea Biosciences' Total Operating Expense of $57.36 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Operating Expense for a Biotechnology company?
A good Total Operating Expense depends on the Biotechnology industry context. However, Total Operating Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Operating Expense mean?
A high Total Operating Expense can signal that a stock is expensive relative to its fundamentals. Total operating expense is the primary recurring expense associated with central operations. View historical data on Genocea Biosciences and its competitors. Genocea Biosciences's current Total Operating Expense is $57.36 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Genocea Biosciences stock overvalued right now?
Genocea Biosciences (LTS:0A51) has a current Total Operating Expense of $57.36 Mil. The current Total Operating Expense is $57.36 Mil. Genocea Biosciences' overall GF Score™ is 16/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Operating Expense calculated?
Total Operating Expense is calculated from a company's financial statements. For Genocea Biosciences (LTS:0A51), the current Total Operating Expense is $57.36 Mil as of Mar. 2022. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Genocea Biosciences Business Description

Address 100 Acorn Park Drive, Cambridge, MA, USA, 02140
Genocea Biosciences Inc is a USA-based biopharmaceutical company discovering and developing novel cancer immunotherapies using its proprietary ATLAS platform. The ATLAS platform can profile each patient's CD4+ and CD8+ T cell immune responses to every potential target or antigen identified by next-generation sequencing of that patient's tumor. ATLAS zeroes in on both antigens that activate anti-tumor T cell responses and inhibitory antigens, or Inhibigens , that drive pro-tumor immune responses.
16GF Score

Get the complete analysis for LTS:0A51

Total Operating Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.00
Price